"Narcotic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents inhibiting the effect of narcotics on the central nervous system.
| Descriptor ID |
D009292
|
| MeSH Number(s) |
D27.505.696.543 D27.505.696.663.850.512 D27.505.954.427.550
|
| Concept/Terms |
Narcotic Antagonists- Narcotic Antagonists
- Antagonists, Narcotic
- Opioid Receptor Antagonists
- Antagonists, Opioid Receptor
- Receptor Antagonists, Opioid
- Opioid Antagonists
- Antagonists, Opioid
|
Below are MeSH descriptors whose meaning is more general than "Narcotic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Narcotic Antagonists".
This graph shows the total number of publications written about "Narcotic Antagonists" by people in this website by year, and whether "Narcotic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 4 | 4 |
| 1999 | 2 | 4 | 6 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 4 | 5 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 3 | 6 |
| 2006 | 4 | 0 | 4 |
| 2007 | 4 | 3 | 7 |
| 2008 | 6 | 6 | 12 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 4 | 6 |
| 2013 | 3 | 3 | 6 |
| 2014 | 1 | 1 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 4 | 2 | 6 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 4 | 2 | 6 |
| 2021 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Narcotic Antagonists" by people in Profiles.
-
The effectiveness of a noninterruptive alert to increase prescription of take-home naloxone in emergency departments. J Am Med Inform Assoc. 2023 Mar 16; 30(4):683-691.
-
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
-
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
-
Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021 01 14; 384(2):140-153.
-
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. Drugs. 2020 Oct; 80(15):1509-1524.
-
Identification and Treatment of Opioid Withdrawal and Opioid Use Disorder in the Emergency Department. MedEdPORTAL. 2020 05 15; 16:10899.
-
Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state. J Subst Abuse Treat. 2020 03; 112S:73-78.
-
Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine. Am J Emerg Med. 2020 05; 38(5):975-978.
-
Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
-
Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice. Neuropharmacology. 2020 05 01; 167:107984.